Brind.

Roche and Regeneron Pharmaceuticals are capitalizing on the growing demand for vision care driven by aging populations.

1 report, 1 independent Updated Aug 18

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Hoffmann-La Roche Regeneron Pharmaceuticals

Keep exploring

The entities involved

Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08
Regeneron Pharmaceuticals
American pharmaceutical company
- Regeneron Pharmaceuticals and Wave Life Sciences are being compared as healthcare companies.Sun 14:10

Coverage

Newest first; wire copies grouped

Aug 18GlobeNewswireGlobal Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™ Delray Beach, FL, Aug. 18, 2025 (GLOBE NEWSWIRE) -- North America leads market expansion as companies advance